Psyence Biomedical (PBM) has released an update.
Psyence Biomedical has struck a pivotal licensing agreement with PSYUK, granting them exclusive rights to use proprietary psilocybin formulations for clinical trials and potential commercialization targeting Alcohol Use Disorder and Substance Use Disorder. The deal is founded on PSYUK’s expertise in natural psychedelic extraction and formulation, with further developmental work planned into 2025. This collaboration aims to leverage PSYUK’s intellectual property to advance PBM’s focus on treating psychological trauma and addiction through natural psilocybin.
For further insights into PBM stock, check out TipRanks’ Stock Analysis page.
